Business Wire - Depomed Reports Dose Proportionality of Gabapentin GR at the Endocrine Society’s Annual Meeting
Tuesday, December 23rd, 2008MENLO PARK, Calif. — Depomed, Inc. (Nasdaq:DEPO) announced today that results from two studies of Gabapentin GR support the ability of its improved, extended release formulation to achieve dose-proportional absorption of the pain drug, gabapentin. Gabapentin GR extended release tablets are in development for the treatment of postherpetic neuralgia (PHN), a long lasting pain condition caused by nerve dam…
